Stephane Ciblat,Patrick Deroy,Melissa Leblanc,Jason J. Marineau,Joel Moore,Stephanie Roy,M. Arshad Siddiqui,Kevin Sprott,Dana K. Winter,Anzhelika Kabro,Serge Leger,Tom Miller,Darby Schmidt,Michael Bra
申请号：
US16230353
公开号：
US20190292167A1
申请日:
2018.12.21
申请国别(地区):
US
年份:
2019
代理人:
摘要：
The present invention provides novel compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of cyclin-dependent kinase 7 (CDK7), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.
